Below are brief introductions to COVID-19 disease and the COVID-19 vaccine with links to more information. Scroll down for a list of QUICK FACTS that provide a summary overview of key facts for the disease and the vaccine.
Most coronaviruses, including those causing the common cold, are not associated with significant mortality. The novel SARS-Coronavirus-2 (SARS-CoV-2) identified in 2019 causes a collection of symptoms that can cause severe illness, which has become known as COVID-19. The SARS-CoV-2 virus is contagious1 and infected persons can be asymptomatic2 or exhibit symptoms ranging from mild to severe. Symptoms include fever; chills; cough; shortness of breath/difficulty breathing; fatigue; muscle, joint or body aches; rash; headache; new loss of taste or smell; sore throat; congestion or runny nose; nausea or vomiting and diarrhea.3
Complications of SARS-CoV-2 include pneumonia, acute respiratory failure, Acute, Respiratory Distress Syndrome (ARDS), acute kidney, liver, and heart injury, septic shock, disseminated intravascular coagulation (DIC), rhabdomyolysis (muscle breakdown), chronic fatigue syndrome, blood clots and death. Many complications may be caused by a condition known as a cytokine storm.4
Research on natural immunity from SARS-CoV-2 infection varies and suggests that durable immunity to the virus lasts for at least 20 months5 and may be life-long.6 An August 2021 retrospective study of Israel’s second largest HMO found that natural immunity “confers longer lasting and stronger protection against infection, symptomatic disease, and hospitalization caused by the Delta variant.”7
New ways to make vaccines including new technologies and production platforms, such as mRNA vaccines, have become favored over the older traditional ways to make vaccines in the COVID-19 vaccine race.8 9 Messenger RNA (mRNA) vaccines are gene based vaccines that involve injecting lipid nanoparticles containing mRNA (genetic code) that enable the vaccine to get past the cell wall, into the intracellular space, then causes the cell’s ribosome to make viral proteins (antigen that stimulate the immune system.)10 In essence, an mRNA vaccine tricks the body into producing the viral proteins to trigger an immune response.11
There are two mRNA COVID-19 vaccines licensed and recommended in the U.S. by the U.S. Food and Drug Administration (FDA) and the U.S. Centers for Disease Control and Prevention (CDC).12 13 There are four additional COVID-19 Vaccines are available for use through Emergency Use Authorization (EUA) by the FDA. These vaccines include two mRNA COVID-19 vaccines for use in infants and children aged 6 months through 4 years and for children five through 11 years of age14 and one mRNA COVID-19 vaccine for use in infants aged 6 months through 11 years.15 There is one protein subunit vaccine authorized for use in individuals 12 years of age and older.16
Under EUA authority, the FDA Commissioner may permit unapproved medical products or unapproved uses of approved medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions caused by CBRN (CBRN = chemical, biological, radiological, nuclear) threat agents when there are no adequate, approved, and available alternatives.17 EUA status, however, also shields vaccine manufacturers and providers from liability under the Public Readiness and Emergency Preparedness Act (PREP Act).18
The EUA status granted to these vaccines does not mean that the FDA has evaluated all safety and efficacy data. For example, the CDC reported in July 2021, after general use in the population under EUA status, that COVID-19 vaccines did not prevent infection the fully vaccinated or transmission of the virus by the fully vaccinated.19 Additionally, multiple studies have found that vaccine effectiveness wanes quickly and vaccinated persons may be more at risk of infection.20 21 22 23 24 25 26
NVIC encourages consumers to make informed vaccination decisions and to read the FDA fact sheet and other information and resources provided on our website.